Form 4 for CLRB Cellectar Biosciences, Inc.
Accepted 2026-05-11 20:05:44 ET · period of report 2026-05-07 · accession 0001104659-26-058851 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-05-11 20:05 | 2026-05-07 | CLRB | CARUSO JAMES V | CEO, Dir | P - Purchase | $2.88 | +8,680 | 20.3K | +75% | +$25.0K |
| D | 2026-05-11 20:05 | 2026-05-07 | CLRB | CARUSO JAMES V | CEO, Dir | P - Purchase | $0.01 | +26.0K | 36.1K | +259% | +$260.40 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-07 | P | A | 8,680 | $2.88 | 20,318 | D | — | — | |
| 2 | Derivative | Warrants | 2026-05-07 | P | A | 26,040 | $0.01 | 36,076 | D | $2.88 · 2026-05-07 to — | 26,040 Common Stock | (F1) Expiration dates are as follows: Tranche A shall have a one-year term from the date of stockholder approval; Tranche B shall have a two-year term from the date of stockholder approval; Tranche C shall have a five-year term from the date of stockholder approval. |